drugset
drugset / Trial / NCT05050682

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants

NCT05050682 ↗

Phase 1 Completed 5 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of PF 07304814 administered at a dose of 500 mg \[14C\] PF-07304814 containing approximately 420 nCi \[14C\] PF-07304814 as a constant-rate, continuous IV infusion over 24 hours

Timeline

Start
2021-10-07
Primary completion
2021-12-10
Completion
2021-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject lufotrelvir Small molecule 500 mg Intravenous

Indications

No indication recorded.